![ECOG-ACRIN logo[19516]275×75](https://blog.ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
October 17, 2024
Summaries of recently published ECOG-ACRIN research results
October 17, 2024
September 17, 2024
Summaries of recently published ECOG-ACRIN research results
August 14, 2024
Summaries of recently published ECOG-ACRIN research results
July 3, 2024
Summaries of recently published ECOG-ACRIN research results
April 9, 2024
Summaries of recently published ECOG-ACRIN research results
March 7, 2024
Summaries of recently published ECOG-ACRIN research results
October 19, 2023
Through a series of blood tests and patient questionnaires, this prospective observational study examines how exposures to trauma and other adverse life experiences alter the activity of genes, immune cells, and subsequent health outcomes
August 25, 2023
Summaries of recently published ECOG-ACRIN research results
December 22, 2021
Researchers with the Leukemia, Lymphoma, and Myeloma Committees presented a range of findings pertaining to treatments, patient-reported outcomes, and genomics
May 28, 2021
Researchers with the ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present a wide range of research findings at the 2021 ASCO Annual Meeting
January 25, 2021
This phase I/II study, led by Dr. Jonathon Cohen, is evaluating the combination of ibrutinib and the oral proteasome inhibitor ixazomib in patients with relapsed/refractory mantle cell lymphoma